Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name INCB099280
Synonyms
Therapy Description

INCB099280 is a small molecule inhibitor of CD274 (PD-L1) that prevents binding to PDCD1 (PD-1), potentially inducing an anti-tumor immune response (J ImmunoTherapy Cancer 2022;10, NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
INCB099280 INCB 099280|INCB-099280|INCB 99280|INCB-99280|INCB99280 Immune Checkpoint Inhibitor 149 INCB099280 is a small molecule inhibitor of CD274 (PD-L1) that prevents binding to PDCD1 (PD-1), potentially inducing an anti-tumor immune response (J ImmunoTherapy Cancer 2022;10, NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05879822 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Active, not recruiting TUR | ROU | NZL | HUN | GRC | BRA 3
NCT06337162 Phase I INCB099280 Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) (HCC) Withdrawn USA 0
NCT04242199 Phase I INCB099280 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Active, not recruiting USA | FRA | BEL | AUS 1
NCT05888844 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Active, not recruiting TUR | ROU | NZL | HUN | HRV | FRA | ESP | CAN | BRA | AUS 5


Additional content available in CKB BOOST